Last updated: April 24, 2026
EA014528 (Eurasian Patent Organization): What the scope and claims cover, and where the patent sits in the landscape
What is EA014528 and what does it claim?
EA014528 is an EAPO (Eurasian Patent Organization) drug patent. The dataset required to produce a complete, accurate analysis of its claim set and scope (full claim text, independent/dependent claim structure, the published application/grant status, assignee/applicant, dates, and legal status, plus citation and family documents) is not present in the information provided. Without the actual claim text and bibliographic record, a precise scope mapping by mechanism, compound scope, formulation, dosing, and use restrictions cannot be generated.
What is the claim scope by composition, use, and method—at a level usable for R&D and freedom-to-operate?
A scope analysis for a drug EAPO patent must be anchored to the literal wording of:
- Independent claims (compound, composition, method of treatment, or use)
- Dependent claims that narrow embodiments (specific substituents, dose ranges, patient subsets, formulations, routes, markers, combinations)
- Claim construction hooks (definitions, genus-species language, Markush-like lists, “comprising” vs “consisting of” language, and alternative embodiments)
That claim text is not available here. As a result, any attempt to describe the scope would risk being speculative rather than “hard data.”
What does the patent landscape look like around EA014528 (families, priority chain, overlaps, and claim competition)?
A defensible landscape requires:
- Priority claims and earliest priority date
- Patent family members (WO/EP/RU/KZ/UA and related filings)
- Claim overlap with earlier patents in the same chemical space or therapeutic indication
- Later filings citing EA014528’s family or asserting similar claims (including opposition and invalidation indicators where available)
- Legal status and remaining term in key Eurasian jurisdictions
No bibliographic details for EA014528 (priority, family, assignee, publication/grant number mapping, legal status) or linkable citation trail are provided in the prompt. Without those anchor facts, the landscape cannot be constructed in a way that supports investment or R&D decisions.
How should stakeholders use EA014528 in freedom-to-operate analysis?
Freedom-to-operate mapping needs element-by-element claim charts against candidate products:
- Molecular identity or Markush coverage boundaries
- Whether the claim is directed to a formulation or a method of treatment
- Whether combination therapy is claimed (drug-drug, drug-device, biomarker-guided use)
- Whether dosage and administration schedule are limiting or optional
Those elements are determined by the literal claim language and claim dependencies. The claim set for EA014528 is not provided.
Where are the high-risk infringement vectors if EA014528 is valid and enforceable?
High-risk vectors typically include:
- Substitution of a generic active that falls within a genus claim
- Formulation “workarounds” that still meet the claimed composition constraints
- Off-label vs on-label treatment scope issues if the claim is “use” or “method of treatment”
- Combination therapy coverage if the claim includes co-administered agents or dosing regimens
But the actual infringement vectors for EA014528 depend on the exact claim scope. The necessary claim text is not available.
What is the actionable bottom line for EA014528 right now?
No complete and accurate analysis of scope and claims, and no credible patent landscape positioning, can be produced from the information in the request. A “detailed analysis” in the Bloomberg-style format requested requires the full bibliographic record and the complete claim text.
Key Takeaways
- EA014528’s claim scope and patent landscape cannot be analyzed to a level suitable for R&D or FTO without the full claim text and bibliographic/legal record.
- A correct landscape requires priority chain, family members, citation trail, and legal status; none of those data are included here.
- Any attempt to summarize scope or overlaps without the claim language would be speculative rather than decision-grade.
FAQs
-
Can you summarize EA014528’s independent claims without the claim text?
No. Independent claim scope must be quoted and mapped from the literal wording.
-
Does EAPO patent scope depend on country-by-country enforcement?
Enforceability and term depend on jurisdictions, and landscape analysis must include those legal-status details; none are provided here.
-
How do I determine whether EA014528 covers a formulation vs a method of treatment?
By the claim categories and limiting language in the claim set; the claim set is not included.
-
What is the fastest way to assess overlap with competing products?
Build element-by-element claim charts against candidate actives, compositions, and indications; this requires the exact claims.
-
What data are required to build a patent family and citation landscape?
Priority chain, publication/grant identifiers, and citation links; the necessary EA014528 bibliographic record is not present.
References
[1] Eurasian Patent Organization (EAPO). EAPO patent publication/record for “EA014528” (bibliographic and claim data).
